Literature DB >> 7721571

Headache characteristics in hospitalized patients with Lyme disease.

S N Scelsa1, R B Lipton, H Sander, S Herskovitz.   

Abstract

We reviewed 49 patients consecutively hospitalized for neurologic Lyme disease to determine the frequency and characteristics of recent onset headaches in this group. All patients had positive serum Lyme ELISAs and other neurologic illness excluded. Recent-onset headache occurred in 26 of 49 patients (53%). Patients with headaches more commonly had central nervous system involvement (54% vs 19%, P < .05) and flu-like illness (58% vs 19%, P < .0005). Eight of 26 (31%) met criteria for meningitis or encephalitis with abnormal CSF examinations. All 8 had focal findings (6), cognitive dysfunction (1), or both (1). The remaining 18 patients had recent-onset headaches resembling migraine (9), tension-type headache (5), or neither (4). Antibiotic treatment resulted in complete headache resolution in 11 of 14 patients with available follow-up data. Based on these findings, we conclude that recent-onset headaches are common in patients hospitalized with Lyme disease. Of those with meningitis or encephalitis requiring intravenous antibiotics, all had focal neurologic findings or cognitive abnormalities, not just headaches.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7721571     DOI: 10.1111/j.1526-4610.1995.hed3503125.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  3 in total

1.  Primary Headache Disorders: Focus on Migraine.

Authors:  Anish Bahra
Journal:  Rev Pain       Date:  2011-12

2.  Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease.

Authors:  Raphael B Stricker; Allison K Delong; Christine L Green; Virginia R Savely; Stanley N Chamallas; Lorraine Johnson
Journal:  Int J Gen Med       Date:  2011-09-06

Review 3.  Headache as a Neurologic Manifestation of Systemic Disease.

Authors:  Alexandra N Cocores; Teshamae S Monteith
Journal:  Curr Treat Options Neurol       Date:  2022-03-18       Impact factor: 3.972

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.